RN-1734
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


RN-1734
Description:
RN-1734 is selective antagonist of the TRPV4 channel, completely antagonizes 4αPDD-mediated activation of TRPV4 with comparable, low micromolar IC50s for all three species (hTRPV4: 2.3 μM, mTRPV4: 5.9 μM, rTRPV4: 3.2 μM) [1]. RN-1734 clearly decreases the production of tumor necrosis factor α (TNF-α) and interleukin 1β (IL-1β) without altering the number of olig2-positive cells[2].UNSPSC:
12352005Hazard Statement:
H302, H315, H319, H335Target:
TRP ChannelType:
Reference compoundRelated Pathways:
Membrane Transporter/Ion Channel; Neuronal SignalingApplications:
Neuroscience-NeuromodulationField of Research:
Neurological Disease; CancerAssay Protocol:
https://www.medchemexpress.com/RN-1734.htmlConcentration:
10mMPurity:
99.75Solubility:
DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C)Smiles:
O=S(C1=CC=C(Cl)C=C1Cl)(N(C(C)C)CCNC(C)C)=OMolecular Formula:
C14H22Cl2N2O2SMolecular Weight:
353.31Precautions:
H302, H315, H319, H335References & Citations:
[1]Kato K, et al. Acidosis environment promotes osteoclast formation by acting on the last phase of preosteoclast differentiation: a study to elucidate the action points of acidosis and search for putative target molecules. Eur J Pharmacol. 2011 Aug 1;663 (1-3) :27-39.|[2]Vincent F, et al. Identification and characterization of novel TRPV4 modulators. Biochem Biophys Res Commun. 2009 Nov 20;389 (3) :490-4.|[3]Liu M, et al. TRPV4 Inhibition Improved Myelination and Reduced Glia Reactivity and Inflammation in a Cuprizone-Induced Mouse Model of Demyelination. Front Cell Neurosci. 2018 Nov 5;12:392.Shipping Conditions:
Room TemperatureStorage Conditions:
-20°C, 3 years; 4°C, 2 years (Powder)Scientific Category:
Reference compound1Clinical Information:
No Development ReportedIsoform:
TRPV4CAS Number:
[946387-07-1]
